These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17019537)

  • 1. Therapeutic effectiveness of a single vs multiple doses of erythropoietin after experimental myocardial infarction in rats.
    Moon C; Krawczyk M; Lakatta EG; Talan MI
    Cardiovasc Drugs Ther; 2006 Aug; 20(4):245-51. PubMed ID: 17019537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window.
    Moon C; Krawczyk M; Paik D; Lakatta EG; Talan MI
    Cardiovasc Drugs Ther; 2005 Aug; 19(4):243-50. PubMed ID: 16187008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats.
    Moon C; Krawczyk M; Ahn D; Ahmet I; Paik D; Lakatta EG; Talan MI
    Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11612-7. PubMed ID: 14500913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction.
    Olea FD; Vera Janavel G; De Lorenzi A; Cuniberti L; Yannarelli G; Cabeza Meckert P; Cearras M; Laguens R; Crottogini A
    J Cardiovasc Pharmacol; 2006 Jun; 47(6):736-41. PubMed ID: 16810073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated low-dose of erythropoietin is associated with improved left ventricular function in rat acute myocardial infarction model.
    Ben-Dor I; Hardy B; Fuchs S; Kaganovsky E; Kadmon E; Sagie A; Coleman R; Mansur M; Politi B; Fraser A; Harell D; Okon E; Battler A; Haim M
    Cardiovasc Drugs Ther; 2007 Oct; 21(5):339-46. PubMed ID: 17912622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties.
    Moon C; Krawczyk M; Paik D; Coleman T; Brines M; Juhaszova M; Sollott SJ; Lakatta EG; Talan MI
    J Pharmacol Exp Ther; 2006 Mar; 316(3):999-1005. PubMed ID: 16306273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inhibition of postinfarct ventricle remodeling without polycythaemia following local sustained intramyocardial delivery of erythropoietin within a supramolecular hydrogel.
    Wang T; Jiang XJ; Lin T; Ren S; Li XY; Zhang XZ; Tang QZ
    Biomaterials; 2009 Sep; 30(25):4161-7. PubMed ID: 19539990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window?
    Talan MI; Ahmet I; Lakatta EG
    PLoS One; 2012; 7(4):e34819. PubMed ID: 22529941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramyocardial injection of heart tissue-derived extracellular matrix improves postinfarction cardiac function in rats.
    Dai W; Gerczuk P; Zhang Y; Smith L; Kopyov O; Kay GL; Jyrala AJ; Kloner RA
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):270-9. PubMed ID: 23345062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells.
    Prunier F; Pfister O; Hadri L; Liang L; Del Monte F; Liao R; Hajjar RJ
    Am J Physiol Heart Circ Physiol; 2007 Jan; 292(1):H522-9. PubMed ID: 16997893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin derivate improves left ventricular systolic performance and attenuates left ventricular remodeling in rats with myocardial infarct-induced heart failure.
    Xu K; George I; Klotz S; Hay I; Xydas S; Zhang G; Cerami A; Wang J
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):506-12. PubMed ID: 20881614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitosan hydrogels significantly limit left ventricular infarction and remodeling and preserve myocardial contractility.
    Henning RJ; Khan A; Jimenez E
    J Surg Res; 2016 Apr; 201(2):490-7. PubMed ID: 27020836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of erythropoietin on cardiac remodeling after myocardial infarction.
    Nishiya D; Omura T; Shimada K; Matsumoto R; Kusuyama T; Enomoto S; Iwao H; Takeuchi K; Yoshikawa J; Yoshiyama M
    J Pharmacol Sci; 2006 May; 101(1):31-9. PubMed ID: 16717399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of resveratrol (trans-3,5,4'-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction.
    Burstein B; Maguy A; Clément R; Gosselin H; Poulin F; Ethier N; Tardif JC; Hébert TE; Calderone A; Nattel S
    J Pharmacol Exp Ther; 2007 Dec; 323(3):916-23. PubMed ID: 17875610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat.
    Hale SL; Sesti C; Kloner RA
    J Cardiovasc Pharmacol; 2005 Aug; 46(2):211-5. PubMed ID: 16044033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
    See F; Thomas W; Way K; Tzanidis A; Kompa A; Lewis D; Itescu S; Krum H
    J Am Coll Cardiol; 2004 Oct; 44(8):1679-89. PubMed ID: 15489104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage.
    Ahmet I; Tae HJ; Juhaszova M; Riordon DR; Boheler KR; Sollott SJ; Brines M; Cerami A; Lakatta EG; Talan MI
    Mol Med; 2011; 17(3-4):194-200. PubMed ID: 21170473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nebivolol prevents remodeling in a rat myocardial infarction model: an echocardiographic study.
    Mercanoğlu GO; Pamukçu B; Safran N; Mercanoğlu F; Fici F; Güngör M
    Anadolu Kardiyol Derg; 2010 Feb; 10(1):18-27. PubMed ID: 20150000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of adrenomedullin on left ventricular remodeling after myocardial infarction in rats.
    Nakamura R; Kato J; Kitamura K; Onitsuka H; Imamura T; Marutsuka K; Asada Y; Kangawa K; Eto T
    Cardiovasc Res; 2002 Dec; 56(3):373-80. PubMed ID: 12445878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction.
    Zhang Y; Elsik M; Edgley AJ; Cox AJ; Kompa AR; Wang B; Tan CY; Khong FL; Stapleton DI; Zammit S; Williams SJ; Gilbert RE; Krum H; Kelly DJ
    Int J Cardiol; 2013 Sep; 168(2):1174-85. PubMed ID: 23219315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.